Pten-deficient mice were assigned to a control group fed with a standard chow or an EPA group fed with a 5 % EPA-supplemented standard chow. At 40 weeks, livers from each group were processed to measure triglyceride content, gene expression analysis, Western blotting analysis, and histological examination. Level of serum reactive oxygen species (ROS) was also determined. Forty- and 76-week-old mice were used in tumor burden experiments.
EPA-ameliorated hepatic steatosis in Pten-deficient mice was based on decreased expression of AMPKα1-mediated SREBP-1c and increased PPARα expression. The EPA group exhibited less severe chronic hepatic inflammation compared to the control group, resulting from decreased ROS formation and a dramatically low ratio of arachidonic acid to EPA. Moreover, EPA inhibited development of hepatocellular carcinoma (HCC) in Pten-deficient mice based on an inhibition of MAPK activity and a low ratio of oleic to stealic acid, and a reduction in ROS formation.
EPA ameliorated steatohepatitis and development of HCC in Pten-deficient mice.